Blood Pressure: for the advancement of hypertension research
Publication Venue For
Thirty years with LIFE—a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy
In memoriam: Jiří Widimský Sr. 1925-2020.
Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes–from single pill combinations to monitoring of a nationwide health insurance database
Blood pressure target in patients with hypertension and type-2 diabetes older than 65 years. Is <130/80 mmHg the right target or an excessive objective preventing from achieving the clinical goals we are aiming at?
Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection
Cuff-less measurements of blood pressure: are we ready for a change?
Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers
The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug
In memoriam: Peter Sleight 1929-2020.
The International Society of Hypertension Guidelines 2020–a new drug treatment recommendation in the wrong direction?
Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial?
Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project
How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers
Over-the-counter mouthwash use, nitric oxide and hypertension risk
The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension
Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines?
Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes
The PARAGON-Heart failure trial–another disappointment for heart failure patients with hypertension and preserved ejection fraction
The PARAGON Heart Failure trial–ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction
Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited
Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?
New data on antihypertensive drugs and risk of cancer: should we worry?
2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension
Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study
Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure
In memoriam: Alberto Zanchetti.
New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?
Challenges in oscillometric blood pressure measurement in atrial fibrillation: looking for practical solutions
Renal denervation in hypertension: is it the end or the beginning of a SPYRAL?
Treatment strategies for comorbid conditions lower residual risk in patients with treated hypertension: FOURIER and other randomized outcome trials
The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke
The INTERSALT Study and the complex relationship between salt intake and blood pressure
The Global Burden of Disease Study 2015 and Blood Pressure
Blood Pressure in 2016: increased impact factor and change of editors
The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease
The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg
Hypertension Management by Practice Guidelines
Renal denervation in treatment-resistant hypertension-Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials
Revisiting the pre-hypertension debate: Increasing evidence for treatment-or not
Blood pressure lowering effect of renal sympathetic denervation or placebo? - Building expectations for Symplicity-HTN 3
2013 European society of hypertension/European society of cardiology hypertension guidelines
Primary cardiovascular prevention by Mediterranean diet - The PREDIMED trial
Angiotensin receptor - Neprilysin inhibiton (ARNI) A novel therapeutic concept for management of hypertension and heart failure
Direct renin inhibitors in hypertension Approaching the moment of truth
Increased time varying heart rate and cardiovascular risk in hypertension Benefit of selective I
An appropriate SCORE to assess cardiovascular risk in hypertension?
Renal nerve ablation: Emerging role in therapeutics
High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts A plea for early drug treatment?
Treatment of high blood pressure in acute stroke - The SCAST Study
Antihypertensive therapy and cancer risks?
Cardiovascular risks in HIV patients
Editorial: Blood pressure and migration
Editorial: Hypertension research into the new millennium
Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports
Editorial: Blood Pressure celebrates 20 years of dedication to Nordic hypertension research
Editorial: Blood pressure variability: Emerging role in risk assessment and therapeutics
Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients?
The J-curve phenomenon revisited
Editorial: Critical aspects in hypertension diagnosis and treatment
Editorial: Should we treat prehypertension?
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention for Endpoint reduction in hypertension study
ONTARGET, TRANSCEND and PROFESS - Clarifying, confusing or misleading?
Critical aspects in hypertension diagnosis and treatment
Benefits of hypertension management in diabetes: An opportunity not to be missed
Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective
More focus on therapeutic targets and improved tolerability in hypertension
Management of older hypertensive patients
More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension
A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET
Urgent need to address quality control issues of out-of-office blood pressure measurement and patient risk assessment
Achieving better blood pressure control
Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy
Hypertension and cardiovascular disease: Is arterial stiffness the heart of the matter
New ESH/ESC Guidelines signal progress in hypertension management
Blood pressure control - Slowly getting there through new strategies?
Documentation of endpoint prevention with combination therapy in hypertension is urgently needed
Beta-blockers as sub-optimal treatment for hypertension: Time for first-line therapy revision?
The question of whether diabetes and its cardiovascular risks can be prevented: A realistic DREAM?
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: The LIFE study
Essential hypertension in women
International Standard Serial Number (issn)
Electronic International Standard Serial Number (eissn)